Assessment of Liver Fatty Acid Binding Protein (L-FABP) as a Diagnostic Marker in Non-Alcoholic Fatty Liver Disease

Abdulaziz, Badawy A.; Abdu, Sabry; Amin, Ahmed Mostafa; Menyawi, Ahmed Khayri Abdel Hamid El; Ahmed, Abdelmoneam; Khalil, Medhat A.; Halim, Walid A. Abdel

doi:10.4236/ojgas.2019.96014

Cited by 3 publications

(9 citation statements)

References 18 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it normalized the FABP1 levels in the NAFLD+CM group of animals. This supports previous reports of the direct relationship of the FABP1 levels and the severity of NAFLD [ 41 ].…”

Section: Discussionsupporting

confidence: 93%

“…However, due to its small molecular weight (15 kDa) and its intracellular location, FABP1 is released in the serum in increased quantities in several pathological conditions involving hepatocyte injury and was reported to have a pathogenic role in NAFLD in diabetic patients [ 40 ]. Additionally, FABP1 was considered an early biomarker that determines the extent of fatty liver infiltration in NAFLD patients through increasing steatosis and subsequent activation of the hepatic stellate cells [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

AlNafea

Korish

2021

PPAR Research

View full text Add to dashboard Cite

Camel milk (CM) has a unique composition rich in antioxidants, trace elements, immunoglobulins, insulin, and insulin-like proteins. Treatment by CM demonstrated protective effects against nonalcoholic fatty liver disease (NAFLD) induced by a high-fat cholesterol-rich diet (HFD-C) in rats. CM dampened the steatosis, inflammation, and ballooning degeneration of the hepatocytes. It also counteracted hyperlipidemia, insulin resistance (IR), glucose intolerance, and oxidative stress. The commencement of NAFLD triggered the peroxisome proliferator-activated receptor-α (PPAR-α), carnitine palmitoyl-transferase-1 (CPT1A), and fatty acid-binding protein-1 (FABP1) and decreased the PPAR-γ expression in the tissues of the animals on HFD-C. This was associated with increased levels of the inflammatory cytokines IL-6 and TNF-α and leptin and declined levels of the anti-inflammatory adiponectin. Camel milk treatment to the NAFLD animals remarkably upregulated PPARs (α, γ) and the downstream enzyme CPT1A in the metabolically active tissues involved in cellular uptake and beta-oxidation of fatty acids. The enhanced lipid metabolism in the CM-treated animals was linked with decreased expression of FABP1 and suppression of IL-6, TNF-α, and leptin release with augmented adiponectin production. The protective effects of CM against the histological and biochemical features of NAFLD are at least in part related to the activation of the hepatic and extrahepatic PPARs (α, γ) with consequent activation of the downstream enzymes involved in fat metabolism. Camel milk treatment carries a promising therapeutic potential to NAFLD through stimulating PPARs actions on fat metabolism and glucose homeostasis. This can protect against hepatic steatosis, IR, and diabetes mellitus in high-risk obese patients.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

AlNafea

Korish

2021

PPAR Research

View full text Add to dashboard Cite

show abstract

“…While the age, gender, and height of the three groups were matched. The same outcomes were reported by Abdulaziz et al (10) . There was a notable statistical difference between the NAFLD group's weight and BMI with mean value (I) and control group (II) with relation to BMI (84.5 ± 9.5), (28.76 ± 4.3) in group І and (74.65 ± 7.44), (23.72 ± 3.04) in group II respectively.…”

Section: Discussionsupporting

confidence: 88%

“…Also, Akbal et al (7) stated that there was no age or gender difference between NAFLD patients and controls, and that as compared to the controls, the NAFLD group's BMI was greater. There was male predominance in our study in contrast to both Abdulaziz et al (10) and Akbal et al (7) ; in both groups, women outnumbered men, However, there was no difference between the groups that was statistically significant. some previous studies showed that gender is linked to NAFLD since guys are reported to be more prone to the disease, according to study.…”

Section: Discussioncontrasting

confidence: 81%

Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease

Bahnasawy,

El Gammal,

El Attar

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide; thus, an early and accurate diagnosis will improve the prognosis therapeutic interventions. Aim: To assess the diagnostic value of liver fatty acid binding protein (L-FABP) for liver injury in non-alcoholic fatty liver disease (NAFLD). Patients and methods: This prospective case-control study was conducted at the Hepatology, Gastroenterology, and Infectious Diseases Clinics, Zagagzig University Hospitals, Egypt on 60 participants divided into three groups: 20 members of the NAFLD in group I had high liver enzymes, 20 members of the NAFLD in group II had normal liver enzymes and 20 members of the healthy control group in group III. L-FABP was measured in all subjects. Results: Regarding L-FABP levels, all of the examined groups showed a significant statistical difference; group I had higher levels than groups II and III, whereas group II had higher levels than group III. Conclusion:The diagnostic biomarker fatty acid-binding liver protein is very useful for NAFLD and a good diagnostic tool of fatty liver injury as its concentrations reflect the level invasion of fat into the liver tissue.

show abstract

“…Furthermore, the data from cell viability, lipid content, ROS production, and gene expression analyses evidenced that the effect of the association on lipids was mediated mainly by curcumin, while the cytoprotective effect was principally ascribable to andrographolide. It has been reported that the FABP1 liver level represents a diagnostic marker in NAFLD [ 44 ], and circulating FABP1 have been found to be higher in type 2 diabetes mellitus patients with NAFLD [ 45 ]. We demonstrated that curcumin, alone and associated with andrographolide, reduces FABP1 expression, which has just been identified as a target for the medical treatment of fatty liver disease.…”

Section: Discussionmentioning

confidence: 99%

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

et al. 2023

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is an emerging chronic liver disease worldwide. Curcumin and andrographolide are famous for improving hepatic functions, being able to reverse oxidative stress and release pro-inflammatory cytokines, and they are implicated in hepatic stellate cell activation and in liver fibrosis development. Thus, we tested curcumin and andrographolide separately and in combination to determine their effect on triglyceride accumulation and ROS production, identifying the differential expression of genes involved in fatty liver and oxidative stress development. In vitro steatosis was induced in HepG2 cells and the protective effect of curcumin, andrographolide, and their combination was observed evaluating cell viability, lipid and triglyceride content, ROS levels, and microarray differential gene expression. Curcumin, andrographolide, and their association were effective in reducing steatosis, triglyceride content, and ROS stress, downregulating the genes involved in lipid accumulation. Moreover, the treatments were able to protect the cytotoxic effect of steatosis, promoting the expression of survival and anti-inflammatory genes. The present study showed that the association of curcumin and andrographolide could be used as a therapeutic approach to counter high lipid content and ROS levels in steatosis liver, avoiding the possible hepatotoxic effect of curcumin. Furthermore, this study improved our understanding of the antisteatosis and hepatoprotective properties of a curcumin and andrographolide combination.

show abstract

Assessment of Liver Fatty Acid Binding Protein (L-FABP) as a Diagnostic Marker in Non-Alcoholic Fatty Liver Disease

Cited by 3 publications

References 18 publications

Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

Contact Info

Product

Resources

About